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Recent studies have shown the p19ARF tumor suppressor to be involved in the response to oncogenic stress
by regulating the activity of p53. This response is mediated by antagonizing the function of Mdm2, a negative
regulator of p53, indicating a pathway for tumor suppression that involves numerous genes altered in human
tumors. We previously described a transgenic mouse brain tumor model in which oncogenic stress, provided
by cell-specific inactivation of the pRb pathway, triggers a p53-dependent apoptotic response. This response
suppresses the growth of developing tumors and thus represents a bona fide in vivo tumor suppressor activity.
We further showed that E2F1, a transcription factor known to induce p19ARF expression, was required for the
response. Here, we use a genetic approach to test whether p19ARF functions to transduce the signal from E2F1
to p53 in this tumor suppression pathway. Contrary to the currently accepted hypothesis, we show that a
deficiency in p19ARF has no impact on p53-mediated apoptosis or tumor suppression in this system. All
measures of p53 function, including the level of apoptosis induced by pRb inactivation, the expression of p21
(a p53-responsive gene), and the rate of tumor growth, were comparable in mice with and without a functional
p19ARF gene. Thus, although p19ARF is required in some cell types to transmit an oncogenic response signal to
p53, it is dispensable for this function in an in vivo epithelial system. These results underscore the complexity
of p53 tumor suppression and further indicate the existence of distinct cell-specific pathways that respond to
similar stimuli.
p19ARF was first identified as the product of an alternative
transcript within the p16INK4a gene (20). Deletions of the
INK4a/ARF locus have been found in a variety of human can-
cers (21), and mice nullizygous at the INK4a/ARF locus de-
velop tumors with a high frequency, usually lymphoma and
sarcoma (24). Importantly, mice that specifically lack p19ARF
but retain p16INK4a develop a similar spectrum of tumors (11),
establishing the tumor suppressor function of p19ARF. Recent
studies in fibroblasts in vitro (2, 3, 8, 16, 35) and in B cells in
vivo (4, 23) suggest a role for p19ARF in p53 responses to
oncogenic stress. For example, overexpression of c-Myc, E2F1,
activated Ras, or E1A in primary mouse embryonic fibroblasts
(MEF) induces p53-dependent growth arrest or apoptosis, and
these effects are attenuated in p19ARF null cells. Furthermore,
p53-deficient cells are resistant to p19ARF-induced cell cycle
arrest (11), indicating that p19ARF acts upstream of p53. Bio-
chemical analyses show that p19ARF can bind to Mdm2 and
block Mdm2-induced p53 degradation, thus providing a mo-
lecular mechanism by which p19ARF can activate p53 (10, 19,
26, 32, 33).
These studies suggest a model in which p19ARF acts as a
tumor suppressor by responding to oncogenic signals, possibly
via direct transcriptional activation by E2F transcription fac-
tors (2, 35) and by transmitting the signal to p53 via Mdm2
regulation. Indeed, the development of B-cell lymphoma in
E-myc transgenic mice is significantly accelerated in Ink4a-
ARF/ (8, 23) and ARF/ (4) backgrounds. Since a similar
effect occurs in p53/ mice (7, 23), these observations support
the hypothesis that p53-mediated tumor suppression in this
model is dependent on p19ARF. However, it is not known
whether the same mechanism is broadly operative in diverse
cell types susceptible to p53 tumor suppression.
Here, we address the role of p19ARF in p53-mediated epi-
thelial cell apoptosis and tumor suppression in vivo. Previously,
we developed a transgenic mouse model (TgT121) in which
epithelial brain tumors are initiated by cell-specific expression
of T121, an oncoprotein derived from simian virus 40 (SV40) T
antigen that specifically inactivates pRb and related proteins
p107 and p130 (22, 27). Inactivation of these proteins in cho-
roid plexus (CP) epithelial cells induces aberrant proliferation
and p53-dependent apoptosis, resulting in the development of
slow-growing tumors (Fig. 1A). In a p53 null background, the
T121-induced apoptosis is significantly reduced, and tumor
growth is accelerated sevenfold (Fig. 1A) (27). Thus, the de-
velopment of tumors in this model serves as a paradigm for
oncogenic stress-induced p53-mediated apoptosis and tumor
suppression in epithelial cells in vivo.
Using a genetic approach, we further showed that the p53-
mediated apoptosis in CP is dependent on E2F1 (Fig. 1B) (18).
Hence, based on the observations described above, p19ARF
was a likely candidate for transmitting the signal from E2F1 to
p53 (Fig. 1B). Here, we test this hypothesis by assessing the
effect of p19ARF deficiency on T121-induced p53-dependent
apoptosis and tumor suppression in vivo.
MATERIALS AND METHODS
Generation of p19ARF-deficient TgT121 mice. Characterization of TgT121 trans-
genic mice (C57BL6/J;DBA2) was described previously (22, 27). Mice harboring
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a homozygous deletion of p19ARF exon 1 (C57BL6/J; Sv129) (11) were kindly
provided by C. J. Sherr and M. F. Roussel (St. Jude Children’s Hospital).
TgT121;p19
ARF/ and TgT121;p19ARF/ mice were generated by crossing hemi-
zygous TgT121 mice with p19ARF/ mice through two generations. In all exper-
iments, TgT121;p19ARF/ and TgT121;p19ARF/ littermates were compared to
control for any variability in the genetic background. TgT121;p19ARF/ mice
were generated in a single cross between TgT121 mice and p19ARF/ mice.
TgT121 and p19ARF genotypes were identified by PCR analysis of tail DNA (11,
27).
Histology, proliferation, and apoptosis assays. Brain tissues were fixed, em-
bedded, and sectioned as described (18). Apoptotic cells were detected in sec-
tions using the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) assay (27). Cell proliferation was determined by in situ
immunodetection of bromodeoxyuridine (BrdU) incorporation as described
(18). The significance of differences in apoptosis levels and cell proliferation
levels between mice with different genotypes was evaluated by t test. P  0.05 was
considered significant.
In situ RNA hybridization. Sections were treated and hybridized as previously
described (18). The p21 antisense probe was generated by T7 transcription of an
EcoRI-linearized pBS-KSp21 template. The p19ARF antisense probe was gener-
ated by T3 transcription of a BamHI-linearized pBS-KSp19ARF (a kind gift of
Yue Xiong). Probes were labeled with [-35S]UTP (5  104 cpm/l) and hybrid-
ized to slides at 50°C overnight. For the p19ARF-specific probe, slides were
exposed for 60 days; for the p21-specific probe, slides were exposed for 3 days.
The sense probes did not show any signal above background in both p21 and
p19ARF in situ hybridizations.
RESULTS
p19ARF expression is induced in T121-expressing cells. Since
oncogenic stress in cultured cells results in transcriptional in-
duction of p19ARF (2, 3, 16, 35), we first determined whether
p19ARF transcripts were induced upon T121 expression coinci-
dent with p53 activation in CP. In situ RNA hybridization with
a mouse p19ARF-specific probe detected a clearly positive sig-
nal in CP of TgT121 mice (Fig. 2C), whereas no signal above
background was detected in normal nontransgenic CP (Fig.
2B). As predicted from previous studies, the p19ARF signal was
not dependent on p53, based on the positive signal in TgT121;
p53/ CP (Fig. 2D). Although p19ARF transcripts were clearly
induced in CP by T121, levels were quite low, based on the
requirement for an exposure time of 8 weeks. By comparison,
p21 transcripts induced by the activation of p53 were detected
in 3 days using similar procedures (18) (see Fig. 5). Nonethe-
less, induction of p19ARF transcripts specifically by T121 ex-
pression supported the possibility that p19ARF transmits a sig-
nal to p53.
p19ARF is not required for p53-dependent apoptosis. To test
whether p19ARF is required for the induction of p53-depen-
dent apoptosis by pRb protein inactivation, we generated
TgT121 mice deficient in p19
ARF by a series of backcrosses with
p19ARF/ mice (11). Apoptosis within the CP of several young
(4 and 8 weeks) TgT121;p19
ARF/, TgT121;p19
ARF/, TgT121;
p19ARF/, and p19ARF/ mice was measured in situ using the
TUNEL assay (Fig. 3A). TgT121;p53
/ mouse brain sections
were assessed as a control. Although p53 deficiency dramati-
cally reduced the level of apoptosis, p19ARF deficiency had
little or no effect (Fig. 3A and B). The average apoptosis level
in the CP of TgT121;p19
ARF/ mice was 8.6%  1.9% (n  6).
The average relative apoptosis indices (AI) of TgT121;
p19ARF/ and TgT121;p19
ARF/ CP compared with that of
TgT121;p19
ARF/ CP (100%) were 92.9%  19.2% and
113.0%  23.1%, respectively. The small difference between
the TgT121;p19
ARF/ group (n  6) and the TgT121;p19
ARF/
group (n  6) is not statistically significant (P  0.601). More-
over, as shown previously (27), the relative AI of TgT121;
p53/ CP (n  3) was reduced to 12.4%  8.5%. Thus,
contrary to the hypothesis, these data show that p53-dependent
apoptosis in response to aberrant proliferation of epithelial
cells in vivo does not require p19ARF.
p19ARF deficiency does not interfere with tumor cell cycle.
Recent studies have shown that p19ARF could inhibit cell
growth by a p53-independent pathway (29). Thus, although
p19ARF was clearly dispensable for the p53-dependent apopto-
sis of CP tumor cells, it was possible that p19ARF affected the
tumor cell cycle by unknown p53-independent mechanisms. To
determine whether this was the case, the fraction of prolifer-
ating tumor cells was determined in the presence and absence





p19ARF/ mice of different ages (4 and 8 weeks) were exam-
ined. This analysis indicated that p19ARF deficiency did not
affect the proliferation of CP tumor cells. The average per-
centage of BrdU-positive cells in the CP of TgT121;p19
ARF/
mice was 8.5%  2.2% (n  6). The relative BrdU staining
levels within the CP of TgT121;p19
ARF/ and TgT121;
p19ARF/ mice were 86.5%  21.2% and 107.5%  37.6%,
respectively (n  6 in both cases) (Fig. 3C). Thus, no signifi-
cant effect of p19ARF on tumor cell proliferation was detected
(P  0.288).
p19ARF deficiency does not accelerate CP tumor growth. In
previous studies of TgT121 mice, we showed that tumor growth
was slow, becoming life-threatening only after a mean age of 26
weeks (22). Deficiency of p53 caused acceleration of tumor
FIG. 1. p53 tumor suppression in brain epithelium. The diagram
depicts previously elucidated steps in the development of choroid
plexus tumors in TgT121 mice. (A) Cell-specific expression of the T121
transgene induces proliferation of normally nondividing epithelial cells
by inactivating the pRb family proteins pRb, p107, and p130. p53-
dependent apoptosis is then activated, as evidenced by the 85% reduc-
tion in apoptosis in TgT121;p53
/ mice. (B) Using a genetic approach,
we previously showed that E2F1 acts upstream of p53 to induce apo-
ptosis in response to T121. Previously, E2F1 was shown to activate
p19ARF transcription, and p19ARF was shown to induce p53 activities
by regulating Mdm2 in cultured cells (see the introduction). In the
current report, we tested whether this pathway is operative to induce
p53-dependent apoptosis and suppression of brain epithelial tumors in
vivo.
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growth due to reduced apoptosis, and the animals died by 4
weeks of age (27). Given that neither apoptosis nor prolifera-
tion appeared to be altered by p19ARF deficiency, tumor
growth was predicted to be unaltered as well. However, it was
possible that additional unexpected parameters dependent on
p19ARF could impact either the rate or morphological charac-
teristics of tumor growth. Because TgT121;p19
ARF/ and
TgT121;p19
ARF/ mice simultaneously develop multiple tumor
types, including CP tumors, sarcoma, and lymphoid malignan-
cies (summarized in Table 1), survival does not provide an
appropriate assessment of CP tumor growth. However, unlike
TgT121;p53
/ mice, all TgT121;p19
ARF/ mice survived be-
yond 4 weeks of age to a mean age of 17 weeks. This result
confirms that p19ARF deficiency does not induce a phenocopy
of p53 deficiency.
Further assessment of CP tumor histopathology showed no
detectable differences between TgT121;p19
ARF/ and TgT121;
p19ARF/ CP tumors (for example, compare panels A and B
of Fig. 4). Although survival time is clearly affected by the
combination of TgT121 and altered p19
ARF alleles (Table 1),
evidence indicates that this effect results from exacerbation by
coexisting malignancies. For example, in mice with compound
genotypes, the simultaneous presence of leukemia (induced by
p19ARF deficiency) and CP carcinoma (caused by T121 expres-
sion) resulted in extensive infiltration of leukemia cells into the
brain (Fig. 4C), a phenotype not observed in either individual
background. It is likely that such effects caused the mice to die
at earlier ages (Table 1). In summary, evaluation of CP tumor
growth indicates that p19ARF is not required for suppression of
tumorigenesis in brain epithelium.
FIG. 2. p19ARF transcripts are induced in aberrantly proliferating CP epithelium. RNA in situ hybridization was performed with an antisense
p19ARF RNA probe. (A) Hematoxylin and eosin (H & E)-stained section from the same brain as in panel C shows the morphology of CP in the
lateral ventricle and is in an orientation similar to that of dark-field panels B to D. The borders between brain parenchyma (br) and the ventricles
(V) are depicted with white dashed lines in panels B to D. No p19ARF expression above background is detected in the CP of nontransgenic mice
(B). (Compare the signal in brain with that in CP.) p19ARF transcripts are induced in TgT121 CP (C). T121-induced p19
ARF expression is p53
independent; the level of p19ARF transcripts is similar in TgT121;p53
/ CP (D) and TgT121 CP (C). (A) Bar, 200 m (magnification is the same
in all panels). Sense probe hybridization showed no signal above background (not shown).
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p53 function is intact in CP of p19ARF-deficient mice. Al-
though p19ARF was not required for p53-mediated apoptosis
or tumor suppression in CP epithelium, we considered whether
p53 activity was at all dependent on p19ARF in this cell type.
Furthermore, although unlikely, it was a formal possibility that
the absence of p19ARF had triggered a switch from p53-depen-
dent apoptosis and tumor suppression to p53-independent
functions, thus masking the impact on p53. Hence, we used an
FIG. 3. T121-induced apoptosis and cell proliferation do not require p19
ARF. T121 expression causes abnormal CP cell proliferation and
apoptosis. About 85% of the apoptosis is p53-dependent (27) and requires E2F1 (18). The TUNEL assay was used to detect apoptosis (A).
Apoptosis levels and morphology were indistinguishable between TgT121;p19
ARF/ (a) and TgT121;p19
ARF/ (b) CP. Apoptotic nuclei are stained
and appear black; representative apoptotic cells are indicated by arrows. The bar (b) is equal to 100 m; both panels are of the same magnification.
Quantitative analysis of apoptosis (B) and proliferation (C) in the CP of three mice each at 4 and 8 weeks of age was carried out. Levels are
compared to that of TgT121;p19
ARF/ tissue, which is considered to represent 100%. Average relative values for all mice of each age and genotype
are shown in the left panels. For these data, error bars indicate the variation among mice. In the right panels, data for each mouse are presented,
with error bars indicating the field-to-field variation in counts taken from 10 fields per brain. Different mice were used for apoptosis and
proliferation assays so as to avoid any impact of BrdU incorporation on apoptosis levels. There is no significant difference in apoptotic indexes
between TgT121;p19
ARF/ and TgT121;p19
ARF/ mice (P  0.601). Importantly, the index of TgT121;p19
ARF/ CP was significantly higher than
that of TgT121;p53
/ CP (P  0.05). The level of CP cell proliferation was determined by immunostaining of BrdU incorporated in vivo (C). The
data show that p19ARF deficiency does not significantly alter cell proliferation (P  0.288).
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independent assessment of p53 function to determine whether
p53 remained active in p19ARF-deficient CP.
The p21 gene is a direct transcriptional target of p53 (5). In
previous work, we demonstrated that p53-dependent p21 ex-
pression was indeed induced by T121 in CP (18). Furthermore,
CP tumors that underwent p53 loss of heterozygosity also lost
p21 expression, providing a perfect correlation between loss of
p53 function and loss of p21 expression (12). If p53 activation
were mediated by p19ARF in response to the T121 oncogenic
signal, then p21 induction would not be observed in TgT121;
p19ARF/ CP, as in the case of TgT121;E2F1
/ and TgT121;
p53/ mice (18). Thus, the level of p21 expression in the CP




ARF/ mice (n 	 3 in each case). In all cases, no
difference in p21 induction between TgT121;p19
ARF/ and
TgT121;p19
ARF/ CP was observed (Fig. 5). These results
demonstrate that the p53 pathway induced by oncogenic stress
in CP epithelium does not require p19ARF function.
DISCUSSION
We previously showed that p53 suppresses the growth of
brain epithelial tumors by mediating apoptosis in response to
aberrant proliferation resulting from Rb pathway inactivation
FIG. 4. Tumor growth and morphology are unaffected by p19ARF deficiency. H & E-stained CP tumors from 20-week-old TgT121;p19
ARF/ (A)
and TgT121;p19
ARF/ (B) mice are similar in size and morphology. In contrast, tumors become life-threatening by 4 weeks of age in TgT121;p53
/
mice (D). Leukemia caused by the p19ARF/ mutation is frequently observed invading the brains of TgT121;p19
ARF/ mice (C), a pathology that
is present only in mice with compound genotypes and is thought to further reduce survival time (Table 1). Representative leukemia-filled vessels
in the brain are indicated by arrows. The bar in panel C is equal to 100 m. The bar in panel D is equal to 200 m; panels A, B, and D are of
the same magnification. br, brain tissue.
















ARF/ 12 45 100 0 0 0
TgT121; p19
ARF/ 10 25 100 40 70 20
TgT121; p19
ARF/ 10 17 100 80 70 40
p19ARF/ 23 27 0 70 52 30
a Mice were sacrificed when they appeared ill. All malignancies present at the
time of sacrifice were scored. Most mice with altered ARF alleles harbored
multiple malignancies.
b Including lymphomas and leukemias.
c Including pheochromocytomas and endocrine tumors.
d Two mice of each genotype clearly contained infiltrating leukemia cells, as
shown in Fig. 4C.
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FIG. 5. p53-mediated transactivation of p21 is unaffected by p19ARF deficiency. Brains were examined from nontransgenic (A and B),
TgT121;p19
ARF/ (C and D), TgT121;p19
ARF/ (E and F), and TgT121;p53
/ (G and H) mice. RNA in situ hybridization was performed on brain
sections using an antisense p21 RNA probe and viewed by dark-field microscopy (B, D, F, and H). Adjacent sections were stained with H & E and
viewed by bright-field microscopy to show the location and morphology of the CP (A, C, E, and G). No p21 expression is detected in normal CP
(B). p21 expression is induced by expression of T121 (D) and remains unchanged in the absence of p19
ARF (F). T121-induced p21 expression in CP
requires functional p53 (H) (18). The bar in panel H is equal to 200 m; all panels are of the same magnification. br, brain tissue.
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(27). Although p19ARF is widely believed to generally transmit
oncogenic stress signals to p53 (25, 31), the studies presented
here show that no defects were detected in known p53 re-
sponses in the CP of p19ARF-deficient mice. p53-dependent
apoptosis, tumor suppression, and transcriptional transactiva-
tion all remained unaffected in the absence of p19ARF. Thus,
these studies indicate that p19ARF does not transmit the on-
cogenic stress signal to p53 in this system. Furthermore, since
p19ARF deficiency appeared to have no effect on CP tumor
growth or morphology, p19ARF also does not appear to sup-
press tumors in this cell type by p53-independent mechanisms.
Previous studies by others showed that B-cell lymphoma
induced in transgenic mice by c-myc overexpression is acceler-
ated in Ink4a/ARF/ and ARF/ backgrounds, similar to the
effect observed in p53/ mice (see the introduction). Further
experiments in primary B cells and in B-cell lymphomas indi-
cate that deficiencies in p53, Ink4a/ARF, or ARF also reduce
the level of c-myc-induced apoptosis (4, 23). Moreover, in
c-myc-induced lymphomas, mutation of p53 or deletion of the
Ink4a/ARF locus was frequent. These mutations were mutually
exclusive (23), supporting the idea that p19ARF and p53 are on
the same tumor suppression pathway in B cells. Thus, the fact
that p19ARF was not required for p53-dependent apoptosis and
tumor suppression in brain epithelium indicates that this path-
way is not universal to all cell types and that cell-specific mech-
anisms exist for transmitting an oncogenic stress signal to p53
for tumor suppression. This concept is supported by a recent
report that medulloblastoma induced in mice heterozygous for
patched is accelerated by p53 deficiency but not by p19ARF
deficiency (30). Although the mechanism for p53 tumor sup-
pression in this model is unknown, the result clearly indicates
that p19ARF is not required.
A recent study by K. Tsai and T. Jacks (personal communi-
cation) shows that p19ARF is also dispensable for p53-depen-
dent apoptosis of embryonic central nervous system (CNS)
neurons and ocular lens epithelium. pRb deficiency induces
unscheduled cell proliferation in both cell types, resulting in
p53-dependent apoptosis (13, 15, 17). As in the adult CP, the
response in these cells requires E2F1 (28). Quantitative anal-
ysis of the apoptosis in Rb/ p19ARF/ embryos showed that
p53-mediated apoptosis was unaffected in the CNS and was
only minimally diminished in the lens. Furthermore, p53 trans-
activation and DNA binding remained intact in the absence of
p19ARF. Previous work in the embryonic lens had shown that a
deficiency in both p16Ink4a and p19ARF inhibited p53-depen-
dent apoptosis to a greater extent, although the relative con-
tributions of the two factors could not be resolved (19). Inter-
estingly, in support of cell-specific mechanisms for p53
regulation, Tsai and Jacks (personal communication) show
that p53-dependent proliferation suppression in embryonic pe-
ripheral neurons (13) does appear to depend on p19ARF.
Hence, one or more p19ARF-independent pathways exist
that trigger p53 tumor suppression in response to disrupted
cell cycle regulation in vivo. What is the mechanism? One
possibility is that p19ARF carries out this function when
present, but a compensatory factor signals p53 in its absence,
i.e., a redundancy exists at this step in the pathway. We con-
sider this possibility unlikely since there are no known p19ARF-
related proteins. Thus, any compensatory pathway, such as an
alternative cell-specific pathway, would be unique and hence
interesting.
p19ARF signals to p53 by regulating Mdm2 (10, 19, 26, 32,
33), a protein that specifically binds p53 and targets it for
degradation via the ubiquitin pathway (1, 6). We do not yet
know whether Mdm2 is also the target for p53 regulation in CP
tumor suppression. Mdm2 deficiency in the mouse causes le-
thality in the early embryo (9, 14), so that a cell-specific defi-
ciency will be required to test the role of Mdm2 in this or any
other in vivo tumor model. We do know that E2F1, and pos-
sibly other E2Fs (34), act upstream of p53 to facilitate the
apoptotic response to pRb pathway inactivation in CP (18).
Thus, as with p19ARF, the signal(s) to p53 could be directly
transcriptionally regulated by E2Fs. However, further experi-
mentation will be required to uncover potential candidates. To
this end, we are currently using an array-based approach to
examine the genes whose transcription is induced in response
to T121 in CP in an E2F1-dependent fashion.
In summary, the studies presented here indicate that, al-
though p19ARF signaling to p53 is a critical tumor suppression
mechanism in some cell types, it does not universally mediate
p53 tumor suppression in response to disrupted cell cycle reg-
ulation. Importantly, additional mechanisms, likely dictated by
the cell type, do exist.
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